Robust Cu2+-Modified Black Phosphorus Nanoplatform for Enhanced Drug Delivery and Synergistic Multimodal Tumor Therapy via Metal Ion-Assisted π–π Interactions
Source abstract
Abstract
The application of 2D nanomaterials for drug delivery via π–π interactions has been extensively investigated. However, these interactions often lack robustness in the presence of blood proteins due to the competitive binding of blood proteins, which results from strong π–π-stacking interactions with aromatic protein residues. This can lead to premature drug release and diminished therapeutic efficacy. To address this challenge, we developed a robust 2D delivery/therapeutic biomimetic nanoplatform that enhances the adsorption affinity and targeted delivery efficiency of the chemotherapeutic drug doxorubicin (DOX) by utilizing Cu 2+ -modified black phosphorus nanosheets (BP@Cu 2+ ) through metal ion-assisted π–π interactions. The synergistic interactions between the π-electrons of BP and DOX, mediated by Cu 2+ coordination, form a stable sandwiched π-cation-π stacking complex (BP@Cu 2+ /DOX). This metal-ion-bridged architecture significantly enhances the DOX loading capacity and minimizes premature release in serum. In the acidic tumor microenvironment, this interaction is disrupted, enabling controlled release of both DOX and Cu 2+ ions. Furthermore, the encapsulation of the complex within tumor cell membranes significantly enhances the efficiency of tumor targeting, resulting in a biomimetic nanoplatform (BP@Cu 2+ /DOX-CMs). Combined with near-infrared laser irradiation, this nanoplatform achieves synergistic multimodal therapy by integrating phototherapy, chemotherapy, chemodynamic therapy, and cuproptosis to enhance antitumor efficacy. The study highlights the potential of metal ion-assisted π–π stacking interactions in the development of advanced 2D nanoplatforms, thereby paving the way for innovative biomedical applications utilizing conventional 2D nanomaterials.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications · MXene and MAX Phase Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiation Oncology
Cancer Hospital of Shantou University Medical College
Department of Pharmacology
Shantou University Medical College
Department of Radiology
The First Affiliated Hospital of Shantou University Medical College
Funding
Basic and Applied Basic Research Foundation of Guangdong Province · Li Ka Shing Foundation
References (69)
Show source-provided references
1. 10.1021/acs.cgd.8b0163010.1021/acs.cgd.8b01630 ↗
2. 10.1021/ja010521210.1021/ja0105212 ↗
3. 10.1021/ja034128310.1021/ja0341283 ↗
4. 10.1002/adma.20170345810.1002/adma.201703458 ↗
5. 10.1021/jp060018h10.1021/jp060018h ↗
6. 10.1016/j.cplett.2009.12.01210.1016/j.cplett.2009.12.012 ↗
7. 10.1021/cr500344e10.1021/cr500344e ↗
8. 10.1016/j.cplett.2009.11.06710.1016/j.cplett.2009.11.067 ↗
9. 10.1021/ja503383e10.1021/ja503383e ↗
10. 10.1093/nsr/nwac10410.1093/nsr/nwac104 ↗
11. 10.1002/advs.20210523110.1002/advs.202105231 ↗
12. 10.1002/lpor.20240003510.1002/lpor.202400035 ↗
13. 10.1016/j.actbio.2013.08.01610.1016/j.actbio.2013.08.016 ↗
14. 10.1002/advs.20200303310.1002/advs.202003033 ↗
15. 10.2147/IJN.S20509510.2147/IJN.S205095 ↗
16. 10.1021/ja803688x10.1021/ja803688x ↗
17. 10.1007/s12274-008-8021-810.1007/s12274-008-8021-8 ↗
18. 10.1016/j.addr.2016.06.00110.1016/j.addr.2016.06.001 ↗
19. 10.1016/j.jddst.2023.10473710.1016/j.jddst.2023.104737 ↗
20. 10.1038/srep1087310.1038/srep10873 ↗
21. 10.1021/nn506660610.1021/nn5066606 ↗
22. 10.1021/ja100938r10.1021/ja100938r ↗
23. 10.1039/C5CS00190K10.1039/C5CS00190K ↗
24. 10.1039/C7MH00804J10.1039/C7MH00804J ↗
25. 10.1002/adfm.20180830610.1002/adfm.201808306 ↗
26. 10.1002/adma.20160327610.1002/adma.201603276 ↗
27. 10.1002/adma.20160386410.1002/adma.201603864 ↗
28. 10.1002/jbm.a.3718310.1002/jbm.a.37183 ↗
29. 10.1021/acsami.9b0037410.1021/acsami.9b00374 ↗
30. 10.1021/acsami.8b0027610.1021/acsami.8b00276 ↗
31. 10.1002/advs.20180051010.1002/advs.201800510 ↗
32. 10.1021/acs.chemmater.7b0110610.1021/acs.chemmater.7b01106 ↗
33. 10.1039/C8SC04844D10.1039/C8SC04844D ↗
34. 10.1021/jp900013e10.1021/jp900013e ↗
35. 10.1158/0008-5472.CAN-10-266410.1158/0008-5472.CAN-10-2664 ↗
36. 10.1016/j.pmatsci.2023.10114510.1016/j.pmatsci.2023.101145 ↗
37. 10.1038/s41467-020-16513-010.1038/s41467-020-16513-0 ↗
38. 10.1016/S0040-4020(01)90691-X10.1016/S0040-4020(01)90691-X ↗
39. 10.1063/1.173986710.1063/1.1739867 ↗
40. 10.1016/j.apsusc.2022.15361810.1016/j.apsusc.2022.153618 ↗
41. 10.1021/acs.langmuir.6b0045610.1021/acs.langmuir.6b00456 ↗
42. 10.1021/mp100245u10.1021/mp100245u ↗
43. 10.1021/acsnano.3c0712310.1021/acsnano.3c07123 ↗
44. 10.1002/9780470602539.ch110.1002/9780470602539.ch1 ↗
45. 10.1016/j.nantod.2023.10191110.1016/j.nantod.2023.101911 ↗
46. 10.1016/j.colsurfb.2020.11146710.1016/j.colsurfb.2020.111467 ↗
47. 10.1021/acsnano.0c0945410.1021/acsnano.0c09454 ↗
48. 10.1002/anie.20200778610.1002/anie.202007786 ↗
49. 10.1016/j.mtbio.2022.10022810.1016/j.mtbio.2022.100228 ↗
50. 10.1186/s11671-018-2728-610.1186/s11671-018-2728-6 ↗
51. 10.7150/thno.857510.7150/thno.8575 ↗
52. 10.1515/nanoph-2021-008510.1515/nanoph-2021-0085 ↗
53. 10.1002/adfm.20220718110.1002/adfm.202207181 ↗
54. 10.1002/adfm.20200439710.1002/adfm.202004397 ↗
55. 10.1002/anie.20181087810.1002/anie.201810878 ↗
56. 10.1007/s44211-024-00631-610.1007/s44211-024-00631-6 ↗
57. 10.1002/adma.20170487710.1002/adma.201704877 ↗
58. 10.1002/adhm.20230041010.1002/adhm.202300410 ↗
59. 10.1038/s41571-020-0341-y10.1038/s41571-020-0341-y ↗
60. 10.1126/science.abf052910.1126/science.abf0529 ↗
61. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
62. 10.1016/j.lfs.2023.12222310.1016/j.lfs.2023.122223 ↗
63. 10.1186/s13578-022-00948-710.1186/s13578-022-00948-7 ↗
64. 10.1002/VIW.2023000110.1002/VIW.20230001 ↗
65. 10.1126/sciadv.abb727210.1126/sciadv.abb7272 ↗
66. Aslakson C. J. · Cancer Res. · 1992 · 52 · 1399
67. 10.1158/0008-5472.CAN-04-184410.1158/0008-5472.CAN-04-1844 ↗
68. 10.3390/nano1111313210.3390/nano11113132 ↗
69. 10.1016/j.lfs.2020.11759910.1016/j.lfs.2020.117599 ↗